CTIS2024-513901-30-00招募中1 期
ong-term Follow-up of Subjects With Sickle Cell Disease Treated With Ex Vivo Gene Therapy Using Autologous Hematopoietic Stem Cells Transduced With a Lentiviral Vector - LTF-307
Bluebird Bio Inc.0 个研究点目标入组 88 人开始时间: 2024年5月14日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 88
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 0 至 64（—）
- 性别
- All
入选标准
- •Provision of written informed consent for this study by subject, or as applicable, subject's parent(s)/ legal guardian(s), Treated with drug product for therapy of SCD in a bluebird bio-sponsored clinical study
排除标准
- •There are no exclusion criteria for this study.
研究者
相似试验
招募中
3 期
Long-term Follow-up of Subjects With Sickle Cell Disease Treated With Ex Vivo Gene Therapy Using Autologous Hematopoietic Stem Cells Transduced With a Lentiviral Vector2024-513901-30-00Bluebird Bio Inc.3
尚未招募
4 期
A study that helps in Observing patients suffering from Sickle Cell Disease, when given a treatment of crizanlizumab in Middle Eastcountries and India (SPOTLIGHT)CTRI/2022/06/043467ovartis Healthcare Pvt Ltd
Enrolling By Invitation
不适用
Long-term Follow-up of Subjects with Sickle Cell Disease Treated with Ex Vivo Gene TherapySickle Cell DiseaseNCT04628585bluebird bio85
终止
不适用
Prospective, Observational Study in Sickle Cell Disease Patients on Crizanlizumab Treatment in Middle East Countries and IndiaSickle Cell DiseaseNCT05020873Novartis Pharmaceuticals44
招募中
不适用
Sickle Cell Outcome ResearchSickle cell diseaseNL-OMON29491A1,000